Apnimed moved ahead with an IPO filing while the FDA reviews its sleep apnea drug, marking a step toward a potential public-market catalyst for the Cambridge, Massachusetts-based biotech. The company revealed Nasdaq plans after years of earlier attempts toward the milestone. The timing matters for commercialization and financing strategy: an IPO can provide runway as FDA review timelines approach decision points and as the company prepares for potential launch obligations. For investors watching the biotech pipeline, Apnimed’s filing illustrates continued appetite for clinical-stage assets with regulatory review catalysts and clearer binary events ahead.